Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care has barely kept pace with the broader markets over the past 52 weeks,…
Bellicum Pharmaceuticals saw its shares rise early on Thursday after the firm announced a critical decision from the FDA.
Pfizer shares were relatively muted after the pharma giant provided an update for its late-stage kidney trial.
Usually, when companies are being acquired they receive a premium on their share price. This does not seem to be the case for Analogic. Is this fair for shareholders?
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Selecta Biosciences saw its shares sink on Tuesday after the company presented new data from patients receiving SEL-212 for the treatment of chronic severe gout.
Spectrum Pharmaceuticals saw its shares make a handy gain early on Tuesday after the firm provided an update on its midstage non-small cell lung cancer study.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid treatment…
Surface Oncology intends to price 6 million shares to result in an initial public offering valued up to more than $103 million.
Therapix Biosciences shares made a solid gain to start the week after it announced topline results for its cannabinoid product platform.
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.
Menlo Therapeutics shares were slaughtered early on Monday after the firm issued an update for its midstage clinical trial for patients with atopic dermatitis.
Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy to treat an inherited disease to treat the leading cause of gene-related infant death.
If interest rates continue higher, these five health care companies with floating rate debt could face some major issues.
